---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017582"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:57:45.769684+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aerovate Q3 net loss widens to $13.6M; trial enrollment delays, cash runway to 2H25

## Summary
- Net loss $13.6M for Q3 2022 vs $6.2M in Q3 2021; R&D expenses tripled to $10.8M.
- Cash and investments $142.6M as of Sep 30, 2022, down from $167.4M at Dec 31, 2021; runway into 2H25.
- IMPAHCT Phase 2b/3 trial enrollment delayed; topline data expected Q4 2023 or Q1 2024.
- Expanded IP with two new U.S. patents (11,413,289 and 11,464,776) issued; notice of allowance for another.
- Sanjeev Khindri joined as SVP Clinical Development; brings respiratory and PAH experience.

## SEC filing metadata
- accession: 0001558370-22-017582
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000155837022017582/0001558370-22-017582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000155837022017582/tmb-20221114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017582
- JSON: https://secwatch.observer/filing/0001558370-22-017582.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017582.txt

## Key facts
- Earnings Releases
  Jade Biosciences, Inc. reported the quarter ended September 30, 2022 results: net income $13.6 million.
  - Period: the quarter ended September 30, 2022
  - Net income: $13.6 million
  - Result: reported results
  source text: On November 14, 2022, Aerovate Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1798749/000155837022017582/0001558370-22-017582-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.